北京：商保创新药可不受“一品两规”限制

Core Viewpoint - The Beijing Municipal Medical Security Bureau and other departments have issued measures to support the high-quality development of commercial health insurance, particularly focusing on the clinical application of innovative drugs and medical devices [1] Group 1: Support for Innovative Drugs - The measures propose to support the rapid listing of innovative drugs through a green channel, which will not be included in the basic medical insurance self-payment rate indicators and the monitoring scope of alternative products in centralized procurement [1] - Commercial insurance innovative drugs will not be affected by the number of drugs in the medical institution's drug list or the drug expenditure ratio [1] - Innovative drugs can bypass the "one product, two regulations" restriction, exploring a "dual-channel" mechanism to ensure supply in designated medical institutions or contracted pharmacies [1] Group 2: Payment and Reimbursement Policies - Costs for eligible new drugs and technologies will not be included in the DRG (Diagnosis-Related Group) payment standards and will be paid separately [1] - Cases involving the application of commercial insurance innovative drugs will not be included in the medical insurance payment range based on disease groups, and will be paid after a review and evaluation process [1]